RC
CAI

Renaissance Capital’s Caris Life Sciences CAI Stock Holding History

Renaissance Capital’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$826K Buy
43,484
+29,055
+201% +$635K 0.6% 30
2025
Q4 		$389K Sell
14,429
-14,031
-49% -$395K 0.28% 36
2025
Q3 		$861K Buy
+28,460
New +$908K 0.48% 29

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Renaissance Capital's CAI Position: Q1 2026 in Review

Renaissance Capital increased its Caris Life Sciences (CAI) stake by 201% in Q1 2026, buying an estimated $635K and bringing the position to 43,484 shares worth $826K. The position accounts for 0.6% of the portfolio, ranked #30.

Renaissance Capital first reported a position in CAI in Q3 2025 and has held it in 3 quarters since. The position peaked at $861K in Q3 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Renaissance Capital held 43,484 shares of Caris Life Sciences worth $826K as of Q1 2026.
  • Renaissance Capital bought 29,055 Caris Life Sciences shares in Q1 2026, an estimated $635K.
  • Caris Life Sciences made up 0.6% of Renaissance Capital's portfolio in Q1 2026, its #30 holding.
  • Renaissance Capital first reported a position in Caris Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • Renaissance Capital's Caris Life Sciences position peaked at $861K in Q3 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Renaissance Capital's 13F filing for Q1 2026, filed 7 May 2026.